EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, today announced that new proof-of-concept preliminary data from its ongoing China clinical study evaluating ET140202 for the treatment of AFP-positive hepatocellular carcinoma (AFP+ HCC) will be presented as a late-breaking oral presentation at the 4th Annual CAR-TCR Summit in Boston, Massachusetts, September 4-7, 2018.
The presentation details are listed below and are accessible on the 4th Annual CAR-TCR Summit website:
Presentation Title: Case Report of Regression of Metastatic Liver
Cancer After ET140202 T-Cell Therapy
Session Title: Late
Breaking Abstracts
Date & Time: Wednesday, September 5,
2018 from 9:15 a.m. – 9:35 a.m. ET
Location: Seaport
Hotel & World Trade Center
Presentation Title: Improvement of Safety in T-cell
Immunotherapies for the Treatment of Cancer
Session Title:
Overcoming CAR-T Toxicity in Solid Tumors (Agenda 1)
Date & Time:
Friday, September 7, 2018 from 1:00 p.m. – 1:30 p.m. ET
Location:
Seaport Hotel & World Trade Center
About Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. is a privately held clinical stage biopharmaceutical company focused on developing novel T-cell therapies that harness the evolutionary power of the immune system. Its core technology platforms center around its proprietary ARTEMIS™ T-cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of multiple solid and hematologic tumors.
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.
